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Cyclooxygenase Regulates Angiogenesis
Induced by Colon Cancer Cells
COX-1 and COX-2. COX-1 is constitutively expressed
in many tissues and cell types (Williams et al., 1997) but
in some cases is increased during differentiation (Smith
Masahiko Tsujii,²³ Sunao Kawano,²
Shingo Tsuji,² Hitoshi Sawaoka,²
Masatsugu Hori,² and Raymond N. DuBois*³
et al., 1993). By contrast, the expression of COX-2 is*Departments of Medicine and Cell Biology
frequently up-regulated by mitogens, cytokines, and tu-Vanderbilt University Medical Center
mor promoters. Greater than 80% of colon cancers inVA Medical Center
humans have increased COX-2 levels when comparedNashville, Tennessee 37232
to adjacent normal tissue (Williams et al., 1997). COX²First Department of Medicine
inhibitors exhibit dramatic antineoplastic activity in aOsaka University School of Medicine
number of tumor model systems. These include colonOsaka 565-0871
cancer cells implanted into nude mice, tumor productionJapan
in APC mutant mice, and carcinogen-induced tumors in
rats (Oshima et al., 1996; Sheng et al., 1997; Kawamori
et al., 1998). In one such study, Seed et al. demonstratedSummary
that topical administration of a nonselective COX inhibi-
tor (diclofenac) reduced the growth of colon-26 cells,To explore the role of cyclooxygenase (COX) in endo-
which express COX and produce PGE2, when implantedthelial cell migration and angiogenesis, we have used
into nude mice (Seed et al., 1997). In this study, thetwo in vitro model systems involving coculture of
authors made the important observation that the antitu-
endothelial cells with colon carcinoma cells. COX-2-
mor effect of diclofenac was due to an antiangiogenic
overexpressing cells produce prostaglandins, proan- effect (Seed et al., 1997). This raises the possibility that
giogenic factors, and stimulate both endothelial mi- elevated COX, especially COX-2, plays a role in the
gration and tube formation, while control cells have growth of certain colon cancer cells due to its ability to
little activity. The effect is inhibited by antibodies to act as a tumor promoter via stimulation of angiogenesis.
combinations of angiogenic factors, by NS-398 (a se- Such a mechanism might also explain the 90% inhibition
lective COX-2 inhibitor), and by aspirin. NS-398 does of the growth of COX-2-positive HCA-7 tumors in vivo
not inhibit production of angiogenic factors or angio- following COX-2 inhibitor treatment (Sheng et al., 1997).
genesis induced by COX-2-negative cells. Treatment Recent studies have confirmed the hypothesis that
of endothelial cells with aspirin or a COX-1 antisense tumor growth, in general, is dependent on angiogenesis
oligonucleotide inhibits COX-1 activity/expression and (Folkman, 1990). Any significant increase in tumor mass
suppresses tube formation. Cyclooxygenase regu- must be preceded by an increase in the vascular supply
lates colon carcinoma-induced angiogenesis by two to deliver nutrients and oxygen to the tumor. The ability
mechanisms: COX-2 can modulate production of angi- of a tumor to induce angiogenesis represents an essen-
ogenic factors by colon cancer cells, while COX-1 reg- tial step for tumor growth beyond 2±3 mm in size. Based
ulates angiogenesis in endothelial cells. on the work published by Seed et al. (1997) and our
previous findings that NSAID treatment limits tumor
growth in a number of different model systems, we hy-
pothesized that COX is involved in angiogenesis.Introduction
In order to test this hypothesis, we have employed
an experimental model in which endothelial and cancerRecent epidemiological studies document a 40%±50%
cells are cocultured (Montesano et al., 1983). We evalu-reduction in mortality from colorectal cancer in individu-
ated two cell types: stably transfected COX-2-overex-als taking nonsteroidal antiinflammatory drugs (NSAIDs)
pressing Caco-2 cells because we had previously re-(Smalley and DuBois, 1997). Since NSAIDs (like aspirin)
ported that COX-2 overexpression could modulate theirare widely believed to have antiinflammatory effects due
phenotype (Tsujii et al., 1997) and HCA-7 cells becauseto their ability to inhibit cyclooxygenase enzyme activity,
they express COX-2 constitutively (Sheng et al., 1997).one possible mechanism for their antitumor properties
We found that these cells produce high levels of angio-is altered metabolism of arachidonic acid. Inhibition of
genic factors, which stimulate endothelial tube forma-cyclooxygenase leads to reduced conversion of arachi-
tion in the coculture model. A selective COX-2 inhibitordonic acid to proinflammatory prostaglandins and other
(NS-398) inhibits both the expression of angiogenic fac-bioactive lipids. In spite of their efficacy as anticancer
tors and endothelial tube formation by COX-2-positiveagents, the precise mechanism(s) for the protective ef-
Caco-2 or HCA-7 cells.
fect of NSAIDs remains unknown. An intense debate is
We also investigated the effect of COX inhibitors on
underway that focuses on a wide range of mechanisms,
endothelial tube formation induced by coculture with
some of which are unrelated to inhibition of cyclooxy- HCT-116 and DLD-1 cell lines, both of which lack COX-1
genase activity (Giardiello et al., 1995; Prescott and or -2 activity. HCT-116 or DLD-1 cells produce angio-
White, 1996; Shiff and Rigas, 1997; Smalley and DuBois, genic factors in levels equivalent to those of COX-2
1997). overexpressing Caco-2 or HCA-7 cells, and in coculture
There are at least two isoforms of cyclooxygenase, they stimulate endothelial tube formation. Aspirin (but
not NS-398) markedly reduced endothelial tube forma-
tion induced by HCT-116 and DLD-1 cells but did not³To whom correspondence should be addressed.
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that both a nonselective COX inhibitor (aspirin) and treat-
ment with COX-1 antisenseoligonucleotide inhibited en-
dothelial tube formation in the HCT-116 coculture model,
although a COX-2 selective inhibitor (NS-398) and COX-2
antisense oligonucleotide showed no inhibitory effect.
These results demonstrate that COX-1 activity in endo-
thelial cells plays an important role in the modulation of
angiogenesis and may be a relevant target for cancer
prevention or treatment in tumors lacking COX-2 ex-
pression.
Results
COX-2 Overexpression in Colon Cancer Cells
Promotes the Motility of Cocultured
Endothelial Cells
Since endothelial cell proliferation and migration are re-
quired early in the angiogenic response, our first series
of experiments was designed to study whether COX-2
expression in colon cancer cells affected these proper-
ties of endothelial cells. To achieve this goal, we used
the experimental set-up shown in Figure 1A. In brief, a
chemotaxis chamber was employed in which the lower
chamber contained colorectal carcinoma cells, and the
upper chamber contained a layer of type I collagen over
which human umbilical vein endothelial cells (HUVECs)
were plated. The number of endothelial cells that mi-
grated through the collagen gel to the bottom of the
lower chamber was scored. As shown in Figure 1B,
HUVECs cocultured with COX-2-transfected Caco-2
cells migrate 8-fold faster than cells cocultured with
control Caco-2 cells (vector alone). This was not due to
an effect on endothelial cell proliferation or to a differ-
ence in binding of HUVECs to collagen (data not shown).
The mobilization of HUVECs in response to COX-2-over-
expressing Caco-2 cells was reduced in the presence of
a selective COX-2 inhibitor (NS-398) in a dose-dependent
manner that correlated well with inhibition of prostaglan-
din production (Figure 1C). COX-2-expressing Caco-2
cells had a 9-fold increase in PGE2 production compared
to mock Caco-2 cells, and NS-398 or aspirin treatmentFigure 1. Effect of COX-2 Expression and COX Inhibitors on Prosta-
glandin Production and Migration of Cocultured HUVECs inhibited PGE2 production in a dose-dependent manner
(A) Schematic diagram of the migration assay chamber. Colonic (Figure 1C). These results show that increased COX-2
carcinoma cells were grown to confluence in the lower chamber, expression in Caco-2 cells stimulates their ability to pro-
the medium was changed, and an upper chamber containing a mote endothelial cell motility through a matrix and that
monolayer of HUVECs plated onto a layer of type I collagen was
inhibition of COX-2 enzyme activity reverses this effect.inserted. The cells were incubated at 378C for 4 hr, and then the
number of cells that had migrated through the collagen gel onto the
filters in the bottom of the upper chamber were counted manually. COX-2 Expression in Colon Cancer Cells Stimulates
(B) Migration of HUVECs cocultured with COX-2-expressing Caco-2
Angiogenesis of Cocultured Endothelial Cellscells. Cell movement was evaluated by the number of cells that
Later stages of angiogenesis require morphological al-migrated toward conditioned medium of mock or COX-2-overex-
terations of endothelial cells, which result in lumen for-pressing Caco-2 cells in the outer chambers. Incubation was per-
formed at 378 for 4 hr, and at the end of the incubation period, mation (Yang and Moses, 1990). To examine this, we
nonmigrated cells on the upper surface of the filter were removed, next employed an in vitro model of angiogenesis in
and the migrated cells were stained and counted manually. which HUVECs are induced to invade a three-dimen-
(C) PGE2 production from mock and COX-2-expressing Caco-2 cells sional collagen gel where they form a network of capil-plus and minus aspirin and NS-398. COX-2-expressing Caco-2 cells
lary-like tubes when stimulated by the appropriate angi-were treated with NS-398 or aspirin at the indicated concentrations
ogenic factors (Figure 2A). Confluent monolayers offor 24 hr prior to harvest. Medium was taken from mock or COX-2-
expressing Caco-2 cells and used for ELISA assay. HUVECs cocultured in this assay chamber (Figure 2A) for
4 days with COX-2-overexpressing Caco-2 cells formed
networks of cord-like structures within the gel (Figure
2B). By contrast, HUVECs cocultured with mock Caco-2affect production of proangiogenic factors. Based on
this result, we evaluated the potential role of endothelial cells showed little invasion or network cord formation.
Quantitative evaluation of cord formation revealed thatCOX activity on endothelial tube formation. We found
Cyclooxygenase, Angiogenesis, and Cancer Prevention
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Figure 2. Effect of COX-2 Expression on An-
giogenesis In Vitro
(A) Schematic diagram of the differentiation
assay chamber. Colonic carcinoma cells
were grown to confluence in the lower cham-
ber, the medium was changed, and an upper
chamber was inserted. The upper chamber
was prepared by plating a monolayer of HU-
VECs onto a very thick layer of type I collagen
followed by incubation at 378C for 24 hr. The
HUVECs were then cocultured with the co-
lonic carcinoma cells at 378C for 4 days, and
following incubation, the number of tube-like
structures that formed in the gel were mea-
sured by total length per field (X 200).
(B) Phase contrast micrographs of HUVECs
grown in collagen gel. (Left panel) HUVECs
cocultured with mock Caco-2 cells did not
form tubular structure, although a few HUVECs
invade into collagen gel. (Right panel) HUVECs
cocultured with COX-2-expressing Caco-2
cells showed tubular structure in the gel.
(C) Quantitative analysis of angiogenesis in
vitro by measuring the length of the tubular
structures formed by HUVECs. The dose-
dependent effect of NS-398 or aspirin treat-
ment on endothelial tube formation was also
assessed. The cell culture medium was
changed daily with fresh addition of NS-398
or aspirin.
coculture with COX-2-overexpressing Caco-2 cells in- PDGF-B, endothelin-1, and iNOS (Abe et al., 1993; War-
ren et al., 1995; Koolwijk et al., 1996; Sankar et al., 1996;creased the length of the endothelial tubular structures
by 5- to 6-fold compared to that seen with mock Caco-2 Yamazaki et al., 1996; Skobe et al., 1997; Papapetro-
poulos et al., 1997). Expression of these mRNAs wascells (Figure 2C). NS-398 or aspirin inhibited this en-
hanced endothelial tube formation in a dose-dependent therefore measured in Caco-2 cells by Northern blot
analysis. COX-2 overexpression was associated withmanner that correlated well with inhibition of prostaglan-
din production (Figure 1C). These results demonstrate increased levels of RNA for these angiogenic factors,
and this effect was inhibited by NS-398 treatment (seethat COX-2 overexpression in Caco-2 cells leads to in-
creasedangiogenesis invitro, which is inhibited by treat- Figure 3A). Using an enzyme-linked immunoassay (ELISA),
we also measured levels of VEGF, bFGF, TBF-b, PDGF,ment with COX inhibitors.
and endothelin-1 in the culture medium of mock and
COX-2-overexpressing Caco-2 cells. The results ofCOX-2 Expression in Colon Cancer
Cells Stimulates Production these assays (shown in Figure 3B) indicate that COX-
2-expressing Caco-2 cells secreted these angiogenicof Angiogenic Factors
Gastrointestinal cancer cells are known to produce a factors into the culture medium. Again, NS-398 treat-
ment clearly inhibited their synthesis and secretion. Wewide variety of factors that may contribute to angiogen-
esis, including VEGF, bFGF,bFGF-binding protein, TBF-b, also measured the production of nitric oxide (NO) from
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Figure 3. Effect of COX-2 Expression in Co-
lon Cancer Cells on the Production of Angio-
genic Factors
(A) Northern blotting analysis to determine
mRNA levels of the indicated angiogenic fac-
tors in Caco-2 cells. Equal loading of RNA
was verified by ethidium bromide staining of
the gel and quantitation of the 18 S and 28 S
bands.
(B) ELISA to determine the concentration of
angiogenic factors in culture medium.
(C) The effect of neutralizing antibodies di-
rected against angiogenic factors on endo-
thelial tube formation. VEGF: 5 mg/ml of anti-
VEGF antibody, 10 mg/ml of control rabbit
IgG, 5 mg/ml of control goat IgG, and 5 mg/
ml of chicken IgG. bFGF:5 mg/ml of anti-bFGF
antibody, 10 mg/ml of control rabbit IgG, 5
mg/ml of control goat IgG, and 5 mg/ml of
chicken IgG. TGF-b1: 5 mg/ml of anti-TGF-b1
antibody, 10 mg/ml of control rabbit IgG, and
10 mg/ml of control goat IgG. PDGF: 5 mg/ml
of anti-PDGF antibody, 10 mg/ml of control
goat IgG, 5 mg/ml of control rabbit IgG, and
5 mg/ml of chicken IgG. VEGF 1 TGF-b1: 5
mg/ml of anti-VEGF antibody, 5 mg/ml of anti-
TGF-b1 antibody, 10 mg/ml of control rabbit
IgG, and 5 mg/ml control goat IgG. bFGF 1
TGF-b1: 5 mg/ml of anti-bFGF antibody, 5 mg/
ml of anti-TGF-b-1 antibody, 10 mg/ml of con-
trol rabbit IgG, and 5 mg/ml of control goat
IgG. VEGF 1 bFGF 1 PDGF: 5 mg/ml of anti-
VEGF antibody, 5 mg/ml of anti-bFGF anti-
body, 5 mg/ml of anti-PDGF, 5 mg/ml of con-
trol goat IgG, and 5 mg/ml of control rabbit
IgG. The cell culture medium was changed
daily with addition of fresh antibodies at the
concentrations given above. Conditioned me-
dium from the COX-2-expressing cells has
similar effects on endothelial migration and
tube formation as coculture with COX-2-
expressing cells. Adding the same combina-
tion of antibodies described above to the
conditioned medium results in inhibition of
endothelial tube formation (data not shown).
mock and COX-2-overexpressing Caco-2 cells to esti- formation, while the combination of at least two neutra-
lizing antibodies (anti-VEGF and anti-TGF-b or anti-bFGFmate nitric oxide synthase (NOS) activity. Cox-2-overex-
pressing Caco-2 cells showed a 3.6-fold increase in NO and anti-TGF-b) or at least three antibodies (anti-VEGF,
anti-bFGF, and anti-PDGF) inhibited endothelial tubeproduction compared with mock Caco-2 cells, and this
was inhibited by treatment with NS-398 (Figure 3B). formation induced by COX-2-overexpressing Caco-2
cells. Endothelin-1 antibody or L-NAME (3 mM), whichWe next investigated which of the angiogenic factors
produced by COX-2-positive Caco-2 cells stimulates completely inhibits the increased production of nitric
oxide by coculture with COX-2-overexpressing Caco-2angiogenesis in the coculture model (Figure 3C) using
neutralizing antibodies or treatment with L-NAME (a ni- cells, had no significant effect on endothelial tube forma-
tion with any combination of other neutralizing antibod-tric oxide synthase inhibitor). Each individual neutraliz-
ing antibody alone had no effect on endothelial tube ies (data not shown). These results indicate that VEGF,
Cyclooxygenase, Angiogenesis, and Cancer Prevention
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bFGF, TGF-b, and PDGF can coordinately regulate angi- with HCT-116 cells (Figure 5B). The combination of neu-
tralizing antibodies that suppressed in vitro angiogen-ogenesis in this system.
esis also inhibited the induction of COX-1 and Ets-1
expression induced by coculture with COX-2-express-Aspirin Inhibits Angiogenesis Induced by Colon
ing Caco-2 or HCT-116 cells, while no combination ofCarcinoma Cells Lacking COX Expression
antibodies significantly inhibited COX-2 expression inTo examine the specificity of the effects observed with
endothelial cells.a COX-2 inhibitor, we evaluated the effect of COX inhibi-
We evaluated the effect of COX-1 and COX-2 expres-tors on in vitro angiogenesis induced by coculture of
sion in HUVECs on their ability to form tubes in collagenHUVECs with HCT-116 cells. These colon carcinoma
gel using either COX-1 or COX-2 antisense oligonucleo-cells lack COX-1 or COX-2 activity (Sheng et al., 1997)
tides. Immunoblot analysis of extracts from antisense-but readily develop a vascular supply in the xenograft
treated HUVECs confirmed that both COX-1 and COX-2model and secrete angiogenic factors in vitro.
antisense oligonucleotides specificallysuppressed COX-1As shown in Figure 4A, coculture with HCT-116 cells
and COX-2 protein expression, respectively. As shownincreased the length of tubular structures formed by
in Figure 5C, COX-1 antisense oligonucleotide, but notHUVECs in the collagen gel 7-fold compared to mock
COX-2 antisense oligonucleotide, inhibited tube forma-Caco-2 cells. HCT-116 cells secrete angiogenic factors
tion of HUVECs in the gel. COX-1 sense oligonucleotideincluding VEGF, bFGF, TGF-b, PDGF, endothelin-1, and
or COX-2 antisense or sense oligonucleotide did notNO (data not shown). Only the combination of at least
show an inhibitory effect on angiogenesis in vitro. Intwo neutralizing antibodies (anti-VEGF and anti-TGF-b,
HUVECs cocultured with COX-2-expressing Caco-2 cellsor anti-bFGF and anti-TGF-b) or at least three neutraliz-
or with HCT-116 cells, COX-1 antisense oligonucleotideing antibodies (anti-VEGF, anti-bFGF, and anti-PDGF)
inhibited the expression of COX-1 and Ets-1, while COX-inhibited tube formation induced by coculture with HCT-
2 antisense oligonucleotide had no significant effect on116 cells (Figure 4A). Endothelin-1 antibody and L-NAME
COX-1 or Ets-1 expression (Figure 5B). These results(3 mM) had no significant effect on tube formation in-
demonstrate that COX-1 produced by endothelial cellsduced by coculture with HCT-116 cells when given in
plays an important role in angiogenesis in this in vitroany combination with other antibodies. These results
assay.confirm our earlier observations with COX-2-expressing
Caco-2 cells that VEGF, bFGF, TGF-b, and PDGF are
involved in angiogenesis in this system. We then investi- HCA-7 and DLD-1 Colon Cancer Cells Produce
Proangiogenic Factors and Stimulategated the effect of NS-398 and aspirin treatment on
VEGF, bFGF, TGF-b, and PDGF production and endo- Angiogenesis of Cocultured
Endothelial Cellsthelial tube formation. As shown in Figure 4B, neither
NSAID had a significant effect on the production and To test the generality of our finding with Caco-2 and
HCT-116 cells, we have characterized two additionalsecretion of these angiogenic factors by HCT-116 cells.
Surprisingly, however, we found that aspirin effectively colorectal cancer cell lines with respect to promotion
of endothelial tube formation and production of proangi-inhibits endothelial tube formation induced by HCT-116
coculture, while NS-398 had no effect (Figure 4C). ogenic factors. We found that HCA-7 cells (which consti-
tutively express COX-2) produced VEGF, bFGF, TGF-b,
and PDGF, which is inhibited by treatment with NS-398COX-1 Is Up-Regulated in Endothelial Cells
or aspirin (Figure 6A). Additionally, we found that bothby Angiogenic Factors
NS-398 and aspirin treatment inhibited endothelial tubeThe finding that aspirin inhibited angiogenesis induced
formation induced by HCA-7 cells in a dose-dependentby COX-negative HCT-116 cells raised the possibility
manner (Figure 6B). Since these cells constitutively ex-that the NSAID is acting on endothelial cells rather than
press COX-2 in culture, these results are not likely dueon the colonic carcinoma cells. More specifically, an-
to a selection artifact of a particular cell type. We alsogiogenic factors might induce COX expression in the
examined another colon cancer cell line (DLD-1) thatendothelial cells. To test this hypothesis, we harvested
has undetectable COX-2 expression and found resultsHUVECs cocultured for 48 hrwith either COX-2-express-
similar to those seen with the HCT-116 cells (Figuresing Caco-2 or HCT-116 cells and measured COX-1,
7A and 7B).COX-2, and Ets-1 protein levels by immunoblot analysis
(Figures 5A and 5B). The Ets-1 gene has been shown
to play an important role in angiogenesis because abro- Cyclooxygenase Inhibitors Have
Antineoplastic Activitygation of its expression can block angiogenesis (Iwa-
saka et al., 1996). COX-1, COX-2, and Ets-1 proteins Our in vitro results have prompted us to evaluate the
antineoplastic properties of NSAIDs in an in vivo tumorwere barely detectable in HUVECs cultured with mock
Caco-2 cells. Significantly, coculture with COX-2-express- xenograft model system. For these experiments, we xe-
nografted colon cancer cells in nude mice and thening Caco-2 cells or with HCT-116 cells induced the ex-
pression of COX-1, COX-2, and Ets-1 in HUVECs (Fig- examined the growth rate of these tumors with and with-
out cyclooxygenase inhibitor treatment. Figure 8A showsures 5A and 5B). NS-398 (10 mM) and aspirin (150 mM)
inhibited Ets-1 expression in HUVECs cocultured with the results with Caco-2 cells. Interestingly, parental
Caco-2 cells (lacking COX-2) do not grow well over theCOX-2-expressing Caco-2 cells (Figure 5A). On the other
hand, as shown in Figure 5B, aspirin (but not NS-398) 28 day time period of this experiment. By contrast, the
COX-2-expressing Caco-2 cells grow at a fairly rapidinhibited the expression of Ets-1 in HUVECs cocultured
Cell
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Figure 4. Production of Angiogenic Factors
from HCT-116 and Endothelial Tube Forma-
tion Induced by Coculture with HCT-116 Cells
(A) In vitro angiogenesis induced by coculture
with HCT-116 cells and the effect of neutraliz-
ing antibodies against angiogenic factors.
(B) The effect of COX inhibitors on production
of angiogenic factors by HCT-116 cells.
(C) The effect of COX inhibitors on induction
of endothelial tube formation by coculture
with HCT-116 cells.
rate, and their growth is inhibited by treatment with both Since HCT-116 cells lack cyclooxygenase-2 expres-
sion, a selective COX-2 inhibitor does not affect theira selective COX-2 inhibitor (NS-398) and the nonselec-
tive NSAID (indomethacin). growth as xenografts in nude mice (Figure 8B and Sheng
Cyclooxygenase, Angiogenesis, and Cancer Prevention
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Figure 5. Western Blot Analysis of COX-1,
COX-2, and Ets-1 in HUVECs and the Effect of
COX-1 or COX-2 Antisense Oligonucleotides
on Ets-1 Expression and Endothelial Tube
Formation
COX-1, -2, and Ets-1 expression in HUVECs
cocultured with mock and COX-2-expressing
Caco-2 cells (A) or HCT-116 cells (B). Anti-
(V 1 T) Ab: 5 mg/ml of anti-VEGF antibody, 5
mg/ml of anti-TGF-b1 antibody, 10 m/ml of
control rabbit IgG, and 5 mg/ml control goat
IgG. Anti-(F 1 T) Ab: 5 mg/ml of anti-bFGF
antibody, 5 mg/ml of anti-TGF-b-1 antibody,
10 mg/ml of control rabbit IgG, and 5 mg/ml
of control goat IgG. Anti-(V 1 F 1 P) Ab: 5
mg/ml of anti-VEGF antibody, 5 mg/ml of anti-
bFGF antibody, 5 mg/ml of anti-PDGF, 5 mg/
ml of control goat IgG, and 5 mg/ml of control
rabbit IgG. COX-1 or COX-2 antisense oligo-
nucleotide (0.5 mM) was transfected into HU-
VECs using 10 mg/ml of lipofectin. (C) The
effect of COX-1 or COX-2 sense or antisense
oligonucleotide transfection into HUVECs on
endothelial tube formation.
et al., 1997). However, a nonselective inhibitor with pref- 1997; Kawamori et al., 1998), but the underlying mecha-
nism of action is still poorly understood. In this report,erence for COX-1 inhibition causes a significant reduc-
we have employed an endothelial cell/colon carcinomation (3-fold) in tumor growth rate (Figure 8B). This result
coculture model system to explore the role of cyclooxy-would have been predicted from the in vitro angiogen-
genase (COX) in tumor-related angiogenesis. We showesis results shown in Figure 4C, further supporting the
that NSAIDs can inhibit angiogenesis by two mecha-notion that endothelial COX-1 activity is important for
nisms: by inhibiting COX-2 activity in colon carcinomatumor-induced angiogenesis.
cells and downregulating production of angiogenic fac-
tors, and by inhibiting COX-1 activity in the endothelial
Discussion cells themselves.
Cyclooxygenase-2, a key enzyme required for the con- COX-2-Overexpressing Colon Cancer Cells
version of arachidonic acid to prostaglandins, plays an Promote Angiogenesis
important role in the promotion of intestinal tumorigene- We show that colon carcinoma cells (Caco-2) that are
forced to express COX-2 stimulate endothelial motilitysis in animal models (Oshima et al., 1996; Sheng et al.,
Cell
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Figure 6. Production of Angiogenic Factors
from HCA-7 Cells and Endothelial Tube For-
mation Induced by Coculture with HCA-7
Cells
(A) The effect of COX inhibitors on production
of angiogenic factors by HCA-7 cells.
(B) The effect of COX inhibitors on induction
of endothelial tube formation by coculture
with HCA-7 cells. Quantitative analysis of an-
giogenesis in vitro by measuring the length
of the tubular structures formed by HUVECs.
The dose-dependent effect of NS-398 or as-
pirin treatment on endothelial tube formation
was also assessed. The cell culture medium
was changed daily with fresh addition of NS-
398 or aspirin.
and tube formation by increased production of proangi- class (i.e., PPARa, PPARg, and PPARd), which acts
directly as a transcription factor upon ligand bind-ogenic factors. Similar activity is seen in untransfected
HCA-7 cells which constitutively express COX-2, sug- ing (Forman et al., 1996). We are currently evaluating
the prostaglandin-mediated transcriptional regulation ofgesting that these results are not an artifact due to
forced overproduction of the enzyme. Since these ef- genes encoding key angiogenic factors (VEGF, TGF-b1,
and PDGF) to further elucidate the mechanisms involvedfects can bereversed by inhibition of COX-2, the produc-
tion of prostaglandins seems to play an important role in the regulation of angiogenesis by COX-2. We have
previously reported that some colon cancer cells andin regulating the production of angiogenic factors by
Caco-2 and HCA-7 cells. The array of prostaglandins rodent intestinal tumors have increased expression of
PPARg (DuBois et al., 1998).produced by Caco-2 cells and their cellular targets is
currently under investigation. We have previously re-
ported that HCA-7 cells produce a wide array of eicosa- Endothelial Cells Upregulate COX-1 in Response
to Angiogenic Factorsnoids (Coffey et al., 1997). These bioactive lipids can
have both autocrine and paracrine effects but usually COX-1 is thought to be expressed constitutively in many
tissues; however, in some cell types it has been reportedact in the microenvironment of the cells from which they
are produced. Two classes of prostaglandin receptors that COX-1 expression is inducible and that its induction
coincides with cell differentiation (Hoff et al., 1993; Mura-exist to transduce signals upon binding of ligand: the
G-coupled cytoplasmic receptor class (i.e., EP1±4 for kami et al., 1995; Ueda et al., 1997). One such cell type
is the endothelial cell. In pulmonary artery endothelialPGE2) (Breyer etal., 1996) and the nuclearPPAR receptor
Cyclooxygenase, Angiogenesis, and Cancer Prevention
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Figure 7. Production of Angiogenic Factors
from DLD-1 Cells and Endothelial Tube For-
mation Induced by Coculture with DLD-1
Cells
(A) The effect of COX inhibitors on production
of angiogenic factors by DLD-1 cells.
(B) The effect of COX inhibitors on induction
of endothelial tube formation by coculture
with DLD-1 cells. Quantitative analysis of an-
giogenesis in vitro by measuring the length
of the tubular structures formed by HUVECs.
The dose-dependent effect of NS-398 or as-
pirin treatment on endothelial tube formation
was also assessed. The cell culture medium
was changed daily with fresh addition of NS-
398 or aspirin.
cells, increased COX-1 gene expression was observed cells could be important in regulating genes required
for endothelial tube formation. If fact, we did observeduring late fetal and early newborn life, a period that
may be critical to successful cardiopulmonary transi- that aspirin treatment or inhibition of COX-1 synthesis
(by antisense oligonucleotide treatment) markedly inhib-tion and function in the newborn (Brannon et al., 1994).
Recently, Narko et al. reported that COX-1-overexpress- ited expression of Ets-1, a transcription factor shown
to be involved in angiogenesis (Iwasaka et al., 1996).ing endothelial cells undergo malignant transformation
whereas COX-2-overexpressing endothelial cells were
difficult to isolate (Narko et al., 1997). These results also
NSAIDs Inhibit Growth of Colon Cancer Xenograftssuggest a role of COX-1 in the regulation of endothelial
Based on the results obtained in the in vitro angiogen-cell biology. Since aspirin (a COX inhibitor) is the most
esis studies, we predicted that parental Caco-2 cellswidely studied NSAID for cancer prevention, we sought
would grow poorly as xenografts in nude mice, whileto determine potential mechanisms for its chemoprotec-
COX-2-overexpressing cells would grow well. In vivotive effects. Here, we demonstrate that COX-1 expres-
experiments supported this hypothesis. Moreover, bothsion and activity in HUVECs regulates tube formation
indomethacin and NS-398 inhibited tumor growth effec-induced by HCT-116 cells. Treatment of HUVECs with
tively. Additional support for our hypothesis comes fromaspirin blocks angiogenesis stimulated by coculture
the finding that a selective COX-2 inhibitor does notwith the COX-negative HCT-116 or DLD-1 cells. There-
fore, prostaglandins produced by COX-1 in endothelial affect HCT-116 xenograft growth, but a nonselective
Cell
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induces cancer cells to produce angiogenic factors and
how COX-1 enhances the angiogenic potential of endo-
thelial cells. However, our results raise novel ideas about
the way in which COX inhibitors carry out their antitumor
effects and open up new opportunities for developing
agents for cancer treatment and prevention in humans.
Experimental Procedures
Reagents and Cells
Neutralizing antibodies against VEGF, bFGF, TGF-b, and PDGFwere
purchased from RandD Systems (Minneapolis, MN cat. #AB-293-
NA, AB-233-NA, AB-101-NA, and AB-20-NA, respectively). Neu-
tralizing antibody against endothelin-1 was purchased from Peptide
Institute (Osaka, Japan) (Masuda et al., 1992). For controls in the
blocking experiments, goat, chicken, or rabbit IgG (Zymed Labora-
tories, San Francisco, CA) was added at an amount equivalent to the
final concentration of IgG (25 mg/ml). The antisense oligonucleotide
sequences for COX-1 and COX-2 were developed in consultation
with AGCT (San Diego, CA). We then evaluated a number of candi-
date sequences to determine which were the best at inhibiting the
expression of COX-1 or COX-2 protein without affecting the expres-
sion of the other COX isoform. Phosphorothioate COX-1 and COX-2
antisense oligonucleotides were selected for the studies presented
here: COX-1, AGAACCGGAGCAAGA; and COX-2, GGAAACATCGA
CAGT, respectively. Sense sequence for each oligonucleotide was
used as controls. Caco-2, DLD-1, and HCT-116 cells were obtained
from the American Type Culture Collection and grown as described
previously (Sheng et al., 1997; Tsujii et al., 1997). HCA-7 cells were
kindly provided by Susan Kirkland (Sheng et al., 1997). Human umbil-
ical vein endothelial cells were obtained from Clonetech (Palo Alto,
CA) and used between passages 2 and 4 for each experiment.
Transfection
A 2.1 kb fragment containing an open reading frame of rat COX-2
was isolated and cloned into the eukaryotic expression vector pCB6,
which contains the CMV promoter for controlling transcription of
the cDNA insert and a neomycin resistance gene expression cas-
sette for G418 selection. This expression vector was transfected
into the Caco-2 cells, and three independent clones showing a 10-
to 12-fold increase in COX-2 expression were isolated by culturing
the cells in medium containing 1.5 mg/ml of G418. We characterized
all three clones and found that they all exhibited the identical pheno-
typic and biochemical alterations. Therefore, the results of our stud-
ies reported here focused on one of these clones. The Caco-2 cellsFigure 8. Effect of Cyclooxygenase Inhibitors on Growth of Xeno-
were transfectedwith vector plasmid aloneand selected in an identi-grafted Cells in Nude Mice
cal fashion. These transfectants were used as controls and desig-
(A) 1 3 106 Caco-2 or COX-2-expressing Caco-2 cells were sus- nated as ªmockº cells.
pended in 0.2 ml of DMEM medium and injected into the dorsal
subcutaneous tissue of athymic nude mice. Mice were given indo- Cell Culture
methacin (3 mg/kg), NS-398 (100 mg/kg), or saline daily by gavage
To quantitate a direct paracrine relationship between tumor cells
tube, as noted in the figure. The treatment was continued for 28
and endothelial cells using neutralizing antibodies and antisense
days. Tumor volumes were determined by external measurement
oligonucleotides, an in vitro coculture system was employed to
according to published methods (Wang et al., 1995). Volume
assay for endothelial tube formation induced by tumor cells.
was determined according to the equation [V 5 L 3 W2] 3 0.5,
To assay the percentage of proliferating cells, a polycarbonate
where V 5 volume, L 5 length and W 5 width. Values expressed
membrane (0.4 micrometer pore size) was coated with type I colla-
are the means 6 SE of 12 xenografts.
gen and placed between the upper and lower well plates. Tumor
(B) 1 3 106 HCT-116 cells were suspended in 0.2 ml of DMEM
cells were grown in the outer chamber, and at confluence, the me-
medium and injected into the dorsal subcutaneous tissue of athymic
dium was changed to serum-free RPMI. Separately, HUVECs sus-
nude mice. The mice were given indomethacin (3 mg/kg), NS-398
pended in serum-free RPMI containing 1% BSA were plated on the
(100 mg/kg), or saline daily by gavage tube. The treatment was
inner chambers and allowed to adhere for 24 hr. Then, the medium
continued for 20 days. Tumor volumes were measured as described
was changed to serum-free RPMI, and the inner chamber was trans-
above.
ferred into the outer chamber. Proliferation of HUVECs was evalu-
ated after 24 hr coculture with mock or COX-2-overexpressing
Caco-2 cells.
To assay for migration of endothelial cells, polycarbonate filtersinhibitor is effective, as shown in Figure 8B. We are
(8 mm pore size) coated with type I collagen were used. Tumor cellscurrently evaluating the effects of treatment with cyclo-
were grown in the outer chamber, and at confluence, the inneroxygenase inhibitors on angiogenesis in these in vivo
chamber was transferred to the outer chamber, and HUVECs were
models. suspended in serum-free RPMI and seeded in the inner chamber.
In conclusion, further investigation will be required to Cell movement was evaluated toward a gradient of conditioned
medium of mock or COX-2-overexpressing Caco-2 cells. The cellsdetermine the precise mechanism(s) by which COX-2
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were incubated at 378 for 4 hr. Following the incubation period, Tumor Growth in Nude Mice
Cells were suspended in 0.2 ml of DMEM medium and were injectednonmigrated cells on the upper surface of the filter were removed,
and the cells that had migrated onto thefilter werecounted manually into the dorsal subcutaneous tissue of athymic nude mice. Tumor
volume was determined by external measurement according to pub-by examination under the microscope.
For the assay of in vitro angiogenesis, tube formation of HUVECs lished methods (Wang et al., 1995). Volume was determined ac-
cording to the equation (V 5 [L 3 W2] 3 0.5, where V 5 volume,in purified collagen was analyzed employing a coculture method.
Tumor cells were grown in the outer chamber, and at confluence, L 5 length, and W 5 width.
the medium was changed with serum-free medium. Separately, for
the preparation of collagen gel, 8 vol of Vitrogen 100 type I collagen Acknowledgments
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